Transdermal Estradiol as a Superior Alternative in Prostate Cancer Management

Evaluating Efficacy, Safety, and Metabolic Impact in Hormone-Sensitive Advanced Disease

Disha Khanna[1], Samdisha Debra[2], Diya Sethi[3], and Matthew Abdel-Missih[4]

[1,2,3,4]The University of Buckingham Medical School, Crewe, United Kingdom

1.7 nmol/L
TESTOSTERONE SUPPRESSION
Achieves therapeutic castrate levels equivalent to standard LHRHa agonists with faster initial decline kinetics.

+7.9% vs. -3.0%
SKELETAL HEALTH IMPACT
Substantial lumbar spine BMD increase at 2 years under tE2, compared to severe osteoporotic loss under LHRHa ($P < 0.001$).

8% vs. 46%
HOT FLUSH INCIDENCE
Remarkably suppressed hot flushes under tE2 therapy, greatly improving patient-reported physical quality of life.

HR 1.11
CARDIOVASCULAR SAFETY
Confirming equivalent long-term cardiovascular safety profile to LHRHa (95% CI 0.80 - 1.53; P = 0.54) via transdermal delivery.

STUDY AIM

To evaluate the therapeutic efficacy, safety profile, and systemic metabolic impact of transdermal estradiol (tE2) as a single-agent alternative to standard luteinizing hormone-releasing hormone agonists (LHRHa) in patients diagnosed with advanced prostate cancer (PCa).

CLINICAL BACKGROUND & RATIONALE

Androgen deprivation therapy (ADT) is the cornerstone of advanced prostate cancer management. However, standard therapy utilizing LHRH agonists causes severe castrate-state side effects, notably bone mineral density (BMD) loss and metabolic dysfunction. This is primarily due to the concurrent depletion of estradiol, the main regulator of skeletal health in men.

Parenteral oestradiol, such as transdermal estradiol (tE2), offers a novel solution: it successfully suppresses testosterone to castrate levels while actively maintaining circulating estradiol. Crucially, parenteral transdermal delivery bypasses the hepatic first-pass metabolism, thereby avoiding the severe cardiovascular (CV) toxicity historically associated with oral estrogen therapies.

The ADT Bottleneck: Standard LHRHa therapy shuts down both testosterone and estradiol, driving profound bone loss and hot flushes. tE2 achieves negative feedback to castrate testosterone but actively preserves circulating estradiol, providing physiological bone protection.

CLINICAL EVIDENCE & STUDY DESIGN

This synthesis evaluates clinical evidence from five trials assessing transdermal estradiol (tE2) in advanced prostate cancer, focusing on efficacy, safety, and metabolic impacts across two key patient cohorts:

- **Hormone-Sensitive Disease**: Large-scale, randomized controlled trials including the multi-stage **PATCH** and **STAMPEDE** trials, comprising 1,362 M0 and 1,128 M1 patients (total 2,490 patients).
- **Castration-Resistant Disease**: Phase II studies investigating low-dose tE2 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.
- **Key Evaluated Outcomes**: Testosterone suppression rates, cardiovascular (CV) safety, bone mineral density (BMD) fluctuations (lumbar spine at 2 years), metabolic profiles (fasting glucose, total cholesterol), and quality of life (QoL) outcomes.

RESULTS: ENDOCRINE EFFICACY & CV SAFETY

- **Endocrine Efficacy**: Evidence from the PATCH and STAMPEDE trials confirms that tE2 patches achieve castrate testosterone suppression equivalent to standard LHRH agonists (1.7 nmol/L), featuring a significantly faster initial testosterone decline.
- **Cardiovascular Safety**: Transdermal delivery completely avoids historical oral CV risks. There was no statistical difference in excess CV toxicity between tE2 and LHRHa therapies (Hazard Ratio: 1.11, 95% CI: 0.80 - 1.53, P = 0.54), confirming the clinical safety of parenteral administration.
- **Metabolic Protection**: Transdermal estradiol improved systemic metabolic profiles, leading to noticeable reductions in fasting glucose levels and total cholesterol relative to standard LHRH agonists.

EFFICACY & TOXICITY SYNTHESIS MATRIX

Clinical Parameter	Standard LHRH Agonists	Transdermal Estradiol (tE2)
Testosterone Castration	Equivalent (1.7 nmol/L)	Equivalent (1.7 nmol/L) (faster onset)
Skeletal Health (BMD)	Severe Loss (-3.0% at 2 years)	Significant Gain (+7.9% at 2 years)
Cardiovascular Safety	Standard Risk	Equivalent Risk (HR 1.11, P = 0.54)
Hot Flushes Incidence	Profound (46%)	Significantly Mitigated (8%)
Metabolic Profiles	Worsened (cholesterol/glucose)	Improved (cholesterol/glucose reduction)
Gynecomastia Incidence	Low (5%)	Elevated (37%)

VISUAL EVIDENCE & TOXICITY TRADE-OFFS



Figure 1: Comparison of skeletal health changes (lumbar spine BMD) at 2 years and key quality-of-life toxicity trade-offs (Hot Flushes vs. Gynecomastia) between tE2 and LHRH agonist therapies based on STAMPEDE/PATCH clinical trials.

DISCUSSION: THE ESTRADIOL PRESERVATION PARADIGM

The concurrent depletion of testosterone and estradiol in standard LHRHa therapy drives many of the severe morbidities associated with ADT. By administering parenteral estradiol, tE2 maintains testosterone castration while actively preserving estradiol. This solves a major clinical bottleneck in prostate cancer management.

Clinical Translation of Skeletal Benefit: The +7.9% increase in lumbar spine BMD at 2 years with tE2 represents a major clinical triumph over LHRHa (-3.0% loss). This bone-preserving effect effectively mitigates the risk of osteoporotic fractures without the clinical complexity, cost, or side effects of adding secondary bone-protection agents (such as bisphosphonates or denosumab).

Quality of Life Trade-Offs: tE2 drastically reduces hot flushes (8% vs. 46%), which are a primary driver of patient discomfort. However, there is a clear trade-off with an increased incidence of gynecomastia (37% vs. 5%). Proactive patient counseling and consideration of prophylactic breast irradiation or tamoxifen are essential clinical strategies.

THERAPEUTIC LIMITATIONS IN CRPC COHORTS

Hormone-Sensitive Restriction: The clinical utility of tE2 is strictly restricted to hormone-sensitive prostate cancer. A Phase II study combining low-dose tE2 (0.2 mg/24h) with paclitaxel poliglumex in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients demonstrated zero clinical activity. No patients achieved a ≥ 50% PSA decline, and the median time to progression was only 4 weeks, highlighting that estrogen pathways cannot rescue castration-resistant states.

CLINICAL CONCLUSIONS

- Transdermal estradiol represents a highly viable, cost-effective, single-agent alternative to standard LHRH agonists for hormone-sensitive advanced prostate cancer.
- It successfully induces therapeutic castration levels of testosterone while preserving bone mineral density, improving metabolic markers, and mitigating hot flushes, without adding any cardiovascular risk.
- The "estradiol-preservation paradigm" offers a patient-centric approach that maintains therapeutic efficacy while directly improving quality of life and bone health.